Corresponding Authors: Yingxia Liu, MD (email@example.com), Zheng Zhang, MD (firstname.lastname@example.org), and Lei Liu, MD (email@example.com), Shenzhen Third People’s Hospital, Second Hospital Affiliated to Southern University of Science and Technology, No. 29, Bulan Road, Longgang District, Shenzhen 518112, China.
Accepted for Publication: March 20, 2020.
Published Online: March 27, 2020. doi:10.1001/jama.2020.4783
Author Contributions: Dr L. Liu had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis. Drs Shen, Z. Wang, Zhao, and Y. Yang contributed equally.
Concept and design: Shen, Z. Wang, Yuan, F. Wang, D. Liu, Zhang, Y. Liu, L. Liu.
Acquisition, analysis, or interpretation of data: Shen, Yang Yang, J. Li, Yuan, D. Li, M. Yang, Xing, Wei, Xiao, Yan Yang, Qu, Qing, L. Chen, Xu, Peng, Y. Li, Zheng, F. Chen, Huang, Jiang, Y. Liu, L. Liu.
Drafting of the manuscript: Shen, Zhao, Yang Yang, J. Li, Yuan, F. Wang, M. Yang, Xing, Wei, Xiao, Yan Yang, Qu, Qing, L. Chen, Xu, Zheng, Huang, Jiang, D. Liu, Y. Liu, L. Liu.
Critical revision of the manuscript for important intellectual content: Shen, Z. Wang, Yang Yang, Yuan, D. Li, Peng, Y. Li, F. Chen, Zhang, Y. Liu, L. Liu.
Statistical analysis: Yuan.
Obtained funding: Yuan, Zhang, Y. Liu, L. Liu.
Administrative, technical, or material support: Shen, Zhao, J. Li, Yuan, F. Wang, D. Li, M. Yang, Yan Yang, Qu, Qing, L. Chen, Zhang.
Supervision: Z. Wang, Yuan, Zhang, Y. Liu, L. Liu.
Conflict of Interest Disclosures: None reported.
Funding/Support: This work was supported by the National Science and Technology Major Project (2018ZX10711001, 2017ZX10103011, 2017ZX10204401), Sanming Project of Medicine in Shenzhen (SZSM201412003, SZSM201512005), China Postdoctoral Science Foundation (2019T120147, 2018M641508), Shenzhen Science and Technology Research and Development Project (202002073000001), National Natural Science Foundation of China (81902058), Shenzhen Science and Technology Research and Development Project (202002073000002), and The Key Technology R&D Program of Tianjin (17YFZCSY01090).
Role of the Funder/Sponsor: The funding agencies had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.
C , Wang
Y , Li
et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet
. 2020;395(10223):497-506. PubMedGoogle ScholarCrossref
Z , McGoogan
JM . Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72 314 cases from the Chinese Center for Disease Control and Prevention. JAMA
. 2020. Published online February 24, 2020. doi:10.1001/jama.2020.2648PubMedGoogle Scholar
L , Xiong
J , Bao
L , Shi
Y . Convalescent plasma as a potential therapy for COVID-19. Lancet Infect Dis
. 2020;S1473-3099(20)30141-9. PubMedGoogle Scholar
CS , Hewlett
AL , Koepsell
et al; Nebraska Biocontainment Unit and the Emory Serious Communicable Diseases Unit. The use of TKM-100802 and convalescent plasma in 2 patients with Ebola virus disease in the United States. Clin Infect Dis
. 2015;61(4):496-502. PubMedGoogle ScholarCrossref
J , Edwards
T , de Lamballerie
et al; Ebola-Tx Consortium. Evaluation of convalescent plasma for Ebola virus disease in Guinea. N Engl J Med
. 2016;374(1):33-42. PubMedGoogle ScholarCrossref
DF , Kalil
AC , Hewlett
et al. Administration of brincidofovir and convalescent plasma in a patient with Ebola virus disease. Clin Infect Dis
. 2015;61(6):969-973. PubMedGoogle ScholarCrossref
B , Zhong
N , Guan
Y . Treatment with convalescent plasma for influenza A (H5N1) infection. N Engl J Med
. 2007;357(14):1450-1451. PubMedGoogle ScholarCrossref
IF , To
KK , Lee
et al. Convalescent plasma treatment reduced mortality in patients with severe pandemic influenza A (H1N1) 2009 virus infection. Clin Infect Dis
. 2011;52(4):447-456. PubMedGoogle ScholarCrossref
T , Radosevich
M . Treatment of severe acute respiratory syndrome with convalescent plasma. Hong Kong Med J
. 2003;9(4):309.PubMedGoogle Scholar
Y , Wong
R , Soo
et al. Use of convalescent plasma therapy in SARS patients in Hong Kong. Eur J Clin Microbiol Infect Dis
. 2005;24(1):44-46.PubMedGoogle ScholarCrossref
Y , Yang
M , Shen
et al Evaluating the accuracy of different respiratory specimens in the laboratory diagnosis and monitoring the viral shedding of 2019-nCoV infections. Preprint. medRxiv
. Preprint posted online February 17, 2020. doi:10.1101/2020.02.11.20021493
J , Blanco
J , del Campo
et al; Spanish Initiative for Epidemiology, Stratification & Therapies for ARDS (SIESTA) Network. Assessment of PaO₂/FiO₂ for stratification of patients with moderate and severe acute respiratory distress syndrome. BMJ Open
. 2015;5(3):e006812. doi:10.1136/bmjopen-2014-006812PubMedGoogle Scholar
C , Yang
Y , Gao
et al Viral architecture of SARS-CoV-2 with post-fusion spike revealed by Cryo-EM. bioRxiv
. Preprint posted online March 5, 2020. doi:10.1101/2020.03.02.972927
KM , Chiueh
TS , Siu
et al. Experience of using convalescent plasma for severe acute respiratory syndrome among healthcare workers in a Taiwan hospital. J Antimicrob Chemother
. 2005;56(5):919-922. PubMedGoogle ScholarCrossref
J , Saavedra-Campos
M , Baillie
et al; Convalescent Plasma Study Group. The effectiveness of convalescent plasma and hyperimmune immunoglobulin for the treatment of severe acute respiratory infections of viral etiology: a systematic review and exploratory meta-analysis. J Infect Dis
. 2015;211(1):80-90. PubMedGoogle ScholarCrossref
KT , Oong
XY , Lim
et al. Viral load and sequence analysis reveal the symptom severity, diversity, and transmission clusters of rhinovirus infections. Clin Infect Dis
. 2018;67(2):261-268. PubMedGoogle ScholarCrossref
MD , Simmons
CP , Thanh
et al. Fatal outcome of human influenza A (H5N1) is associated with high viral load and hypercytokinemia. Nat Med
. 2006;12(10):1203-1207. PubMedGoogle ScholarCrossref
C , Chen
J , Li
et al. A multimechanistic antibody targeting the receptor binding site potently cross-protects against influenza B viruses. Sci Transl Med
. 2017;9(412):eaam5752.PubMedGoogle Scholar
C , Zhang
M , Chen
et al. An IgM antibody targeting the receptor binding site of influenza B blocks viral infection with great breadth and potency. Theranostics
. 2019;9(1):210-231. PubMedGoogle ScholarCrossref
C , Li
W , Drabek
et al A human monoclonal antibody blocking SARS-CoV-2 infection. bioRxiv
. Preprint posted online March 12, 2020. doi:10.1101/2020.03.11.987958
CL , Murakowski
DK , Bournazos
et al. Enhanced clearance of HIV-1-infected cells by broadly neutralizing antibodies against HIV-1 in vivo. Science
. 2016;352(6288):1001-1004. PubMedGoogle ScholarCrossref